Durvalumab

Definition

Durvalumab is an immune checkpoint inhibitor that targets the PD-L1 protein, enhancing the body's immune response against cancer cells. It is primarily used in the treatment of non-small cell lung cancer (NSCLC) and urothelial carcinoma.

5 Must Know Facts For Your Next Test

1. Durvalumab is classified as a monoclonal antibody.
2. It works by blocking the interaction between PD-L1 and its receptors, PD-1 and CD80.
3. Durvalumab is administered via intravenous infusion, typically every two to four weeks.
4. Common side effects include fatigue, cough, and shortness of breath.
5. Patients receiving durvalumab should be monitored for immune-related adverse reactions such as pneumonitis, hepatitis, and colitis.

Review Questions

• What type of cancer treatment is durvalumab categorized under?
• How does durvalumab enhance the body's immune response to cancer?
• What are some common side effects associated with durvalumab therapy?

Related terms

Immune Checkpoint Inhibitor: A class of drugs that block proteins made by certain types of immune system cells and some cancer cells.

PD-L1: A protein that plays a major role in suppressing the adaptive arm of immune responses.

Monoclonal Antibody: Antibodies that are made by identical immune cells that are all clones of a unique parent cell, used to target specific antigens.